Durvalumab completion and re-administration after grade 2 radiation pneumonitis following concurrent chemoradiotherapy for unresectable stage III NSCLC: a single-center real-world study.
Overview & Synopsis
Open access biomedical research article published in BMC Cancer.
Indexed from repository: PubMed Central
(
pmc.ncbi.nlm.nih.gov)
Keyboard Shortcuts:
← / → for pages • + / - for zoom • 0 to fit width
Powered by Mozilla PDF.js v3.11
Document Information
| Document Title | Durvalumab completion and re-administration after grade 2 radiation pneumonitis following concurrent chemoradiotherapy for unresectable stage III NSCLC: a single-center real-world study. |
|---|---|
| Author / Organization | Aoki S, Ariyasu R, Kamima T, Sato Y, Tokumasu K, Anno W, Ogura Y, Kaneko M, Mun M, Ninomiya H, Nishio M, Yoshioka Y |
| Subject & Discipline | BMC Cancer |
| Categories | Medicine & Health |
| Publication Year | 2026 |
| License / Rights | Open Access / Creative Commons |
| Resource Verification | Listed PDF (Verification Pending) |
| Original Host Website |
PubMed Central
(pmc.ncbi.nlm.nih.gov)
|
| File Format | application/pdf (Portable Document Format) |
| Language | EN |
| Catalog ID | DOC-35244 |
| Original Source Link | Visit Source Page on pmc.ncbi.nlm.nih.gov » |